171 related articles for article (PubMed ID: 37430220)
1. Estimating hepatitis B virus prevalence among key population groups for European Union and European Economic Area countries and the United Kingdom: a modelling study.
Trickey A; Bivegete S; Duffell E; McNaughton AL; Nerlander L; Walker JG; Fraser H; Hickman M; Vickerman P; Brooks-Pollock E; Christensen H
BMC Infect Dis; 2023 Jul; 23(1):457. PubMed ID: 37430220
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups.
Falla AM; Hofstraat SHI; Duffell E; Hahné SJM; Tavoschi L; Veldhuijzen IK
BMC Infect Dis; 2018 Feb; 18(1):79. PubMed ID: 29433454
[TBL] [Abstract][Full Text] [Related]
3. Estimates of hepatitis B virus prevalence among general population and key risk groups in EU/EEA/UK countries: a systematic review.
Bivegete S; McNaughton AL; Trickey A; Thornton Z; Scanlan B; Lim AG; Nerlander L; Fraser H; Walker JG; Hickman M; Vickerman P; Johnson H; Duffell E; Brooks-Pollock E; Christensen H
Euro Surveill; 2023 Jul; 28(30):. PubMed ID: 37498533
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: a systematic review update.
Han R; Zhou J; François C; Toumi M
BMC Infect Dis; 2019 Jul; 19(1):655. PubMed ID: 31337339
[TBL] [Abstract][Full Text] [Related]
5. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening.
Hahné SJ; Veldhuijzen IK; Wiessing L; Lim TA; Salminen M; Laar Mv
BMC Infect Dis; 2013 Apr; 13():181. PubMed ID: 23597411
[TBL] [Abstract][Full Text] [Related]
6. Current prevalence of chronic hepatitis B and C virus infection in the general population, blood donors and pregnant women in the EU/EEA: a systematic review.
Hofstraat SHI; Falla AM; Duffell EF; Hahné SJM; Amato-Gauci AJ; Veldhuijzen IK; Tavoschi L
Epidemiol Infect; 2017 Oct; 145(14):2873-2885. PubMed ID: 28891457
[TBL] [Abstract][Full Text] [Related]
7. Estimating the scale of chronic hepatitis C virus infection in the EU/EEA: a focus on migrants from anti-HCV endemic countries.
Falla AM; Ahmad AA; Duffell E; Noori T; Veldhuijzen IK
BMC Infect Dis; 2018 Jan; 18(1):42. PubMed ID: 29338702
[TBL] [Abstract][Full Text] [Related]
8. HIV seroprevalence in five key populations in Europe: a systematic literature review, 2009 to 2019.
Stengaard AR; Combs L; Supervie V; Croxford S; Desai S; Sullivan AK; Jakobsen SF; Santos Q; Simões D; Casabona J; Lazarus JV; de Wit JBF; Amort FM; Pharris A; Nerlander L; Raben D
Euro Surveill; 2021 Nov; 26(47):. PubMed ID: 34823636
[TBL] [Abstract][Full Text] [Related]
9. The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis.
Stockdale AJ; Kreuels B; Henrion MYR; Giorgi E; Kyomuhangi I; de Martel C; Hutin Y; Geretti AM
J Hepatol; 2020 Sep; 73(3):523-532. PubMed ID: 32335166
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of HIV, HCV and HBV in Central Asia and the Caucasus: A systematic review.
Davlidova S; Haley-Johnson Z; Nyhan K; Farooq A; Vermund SH; Ali S
Int J Infect Dis; 2021 Mar; 104():510-525. PubMed ID: 33385583
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association.
Hope VD; Eramova I; Capurro D; Donoghoe MC
Epidemiol Infect; 2014 Feb; 142(2):270-86. PubMed ID: 23714072
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B, hepatitis C and HIV prevalence and related sexual and substance use risk practices among key populations who access HIV prevention, treatment and related services in South Africa: findings from a seven-city cross-sectional survey (2017).
Scheibe A; Young K; Versfeld A; Spearman CW; Sonderup MW; Prabdial-Sing N; Puren A; Hausler H
BMC Infect Dis; 2020 Sep; 20(1):655. PubMed ID: 32894072
[TBL] [Abstract][Full Text] [Related]
13. Associations between the prevalence of chronic hepatitis B among people who inject drugs and country-level characteristics: An ecological analysis.
Syangbo A; Hickman M; Colledge-Frisby S; Leung J; Grebely J; Larney S; Degenhardt L; Trickey A
Drug Alcohol Rev; 2023 Mar; 42(3):569-581. PubMed ID: 36600489
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B and C prevalence and incidence in key population groups with multiple risk factors in the EU/EEA: a systematic review.
Mason LM; Duffell E; Veldhuijzen IK; Petriti U; Bunge EM; Tavoschi L
Euro Surveill; 2019 Jul; 24(30):. PubMed ID: 31362808
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B virus infection in EU/EEA and United Kingdom prisons: a descriptive analysis.
Nakitanda AO; Montanari L; Tavoschi L; Mozalevskis A; Duffell E
Epidemiol Infect; 2021 Jan; 149():e59. PubMed ID: 33487201
[TBL] [Abstract][Full Text] [Related]
16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B infection prevalence by country of birth in migrant populations in a large UK city.
Cochrane A; Evlampidou I; Irish C; Ingle SM; Hickman M
J Clin Virol; 2015 Jul; 68():79-82. PubMed ID: 26071342
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of chronic HCV infection in EU/EEA countries in 2019 using multiparameter evidence synthesis.
Thomadakis C; Gountas I; Duffell E; Gountas K; Bluemel B; Seyler T; Pericoli FM; Kászoni-Rückerl I; El-Khatib Z; Busch M; Schmutterer I; Vanwolleghem T; Klamer S; Plettinckx E; Mortgat L; Van Beckhoven D; Varleva T; Kosanovic Licina ML; Nemeth Blazic T; Nonković D; Theophanous F; Nemecek V; Maly M; Christensen PB; Cowan S; Rüütel K; Brummer-Korvenkontio H; Brouard C; Steffen G; Krings A; Dudareva S; Zimmermann R; Nikolopoulou G; Molnár Z; Kozma E; Gottfredsson M; Murphy N; Kondili LA; Tosti ME; Ciccaglione AR; Suligoi B; Nikiforova R; Putnina R; Jancoriene L; Seguin-Devaux C; Melillo T; Boyd A; van der Valk M; Op de Coul E; Whittaker R; Kløvstad H; Stępień M; Rosińska M; Valente C; Marinho RT; Popovici O; Avdičová M; Kerlik J; Klavs I; Maticic M; Diaz A; Del Amo J; Lundberg Ederth J; Axelsson M; Nikolopoulos G
Lancet Reg Health Eur; 2024 Jan; 36():100792. PubMed ID: 38188273
[TBL] [Abstract][Full Text] [Related]
19. Association between universal hepatitis B prison vaccination, vaccine uptake and hepatitis B infection among people who inject drugs.
Palmateer NE; Goldberg DJ; Munro A; Taylor A; Yeung A; Wallace LA; Mitchell A; Shepherd SJ; Gunson RN; Aitken C; Hutchinson SJ
Addiction; 2018 Jan; 113(1):80-90. PubMed ID: 28710874
[TBL] [Abstract][Full Text] [Related]
20. Impact of hepatitis B vaccination on acute hepatitis B epidemiology in European Union/European Economic Area countries, 2006 to 2014.
Miglietta A; Quinten C; Lopalco PL; Duffell E
Euro Surveill; 2018 Feb; 23(6):. PubMed ID: 29439751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
